Torus

In October 2026, Torus concentrated 58.90% of sales in Flower and 36.74% in Pre-Roll, with smaller positions in Concentrates at 2.73% and Vapor Pens at 1.63%; within this mix, Flower declined year over year by 12.29% but grew month over month by 5.05%, while Pre-Roll slipped 1.91% year over year yet advanced 14.12% month over month. The tail categories diverged, as Concentrates expanded 60.58% year over year but fell 16.26% month over month, and Vapor Pens contracted 10.12% year over year alongside a 37.64% month-over-month drop; combined with a 3.37% year-over-year decrease in average price and a brand-level year-over-year sales decline of 7.51%, this pattern implies Torus is leaning on Pre-Roll momentum to offset Flower headwinds without sustained contribution from inhalables. Torus’s top market remains WA, and within Washington Flower it holds rank 14, which, paired with Flower’s 58.90% share and Pre-Roll’s accelerating 14.12% month-over-month growth, implies the brand’s near-term volume is anchored in core combustibles while premiumized segments are not yet delivering steady lift.

The mix shift signals an execution trade-off: heavier reliance on Flower at rank 14 in Washington and a 5.05% month-over-month Flower uptick provide scale, but the 12.29% Flower year-over-year decline and 37.64% month-over-month drop in Vapor Pens constrain laddering into higher-priced inhalables; meanwhile, Pre-Roll’s 14.12% month-over-month rise against a 1.91% year-over-year dip points to promotional or format-driven bursts rather than durable share capture. With Concentrates up 60.58% year over year but down 16.26% month over month and average price down 3.37% year over year, Torus is trading mix toward volume categories while giving up pricing power, implying the brand’s positioning is skewing value-first in combustibles with underdeveloped premium adjacency in Vapor Pens.